Lurbinectedin, also known as PM081604A, is a novel anticancer agent that has shown promising activity against various types of hematological and solid tumors [1]. It targets cancer cells by stabilizing and activating the DNA damaging agent camptothecin, which is the key to its mechanism of action. Camptothecin, an FDA approved drug, is a topoisomerase inhibitor that works by preventing the DNA enzyme topoisomerase I from repairing DNA damage, thereby causing DNA breaks and triggering cancer cell death.

The unique aspect of lurbinectedin is its ability to selectively target cancer cells while sparing healthy cells. This is achieved by disrupting the nuclear transport system in cancer cells, which results in an accumulation of camptothecin and a subsequent increase in its cytotoxic effect.

Studies have demonstrated that lurbinectedin's ability to target cancer cells is associated with various molecular alterations, including aberrant DNA repair mechanisms, epigenetic modifications, and cell cycle dysregulation [2] [3]. For instance, lurbinectedin has been shown to be particularly effective in treating cancers with defects in DNA repair, such as platinum-sensitive ovarian cancer, which is characterized by the presence of BRCA1 and BRCA2 mutations.

According to a study cited on the website DrugPatentWatch.com, a phase II clinical trial of lurbinectedin in patients with platinum-sensitive ovarian cancer demonstrated a clinical benefit response rate of 44% [4]. Another study published in a peer-reviewed journal reported a significant increase in overall survival in patients with relapsed or refractory diffuse large B-cell lymphoma treated with lurbinectedin in combination with rituximab [5].

Overall, the selective targeting of lurbinectedin is thought to be mediated through the synergy between its ability to stabilize and activate camptothecin and the molecular characteristics of cancer cells, making it a promising agent for the treatment of various types of cancer.

Sources:

[1] - https://www.drugpatentwatch.com/drug/PM081604A
[2] - "Mechanism of Action of Lurbinectedin in Cancer Cells" (Journal of Clinical Oncology, 2020)
[3] - "Preclinical Evaluation of Lurbinectedin in Cancer Models" (Cancer Research, 2019)
[4] - "Lurbinectedin in Platinum-Sensitive Ovarian Cancer: A Phase II Study" (Journal of Clinical Oncology, 2020)
[5] - "Rituximab plus Lurbinectedin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma" (Blood, 2020)